Abstract
Multi-cancer early detection (MCED) testing along with standard of care (SoC) could improve survival outcomes and lower treatment costs but increase screening costs. These estimates may depend on methods for projecting post-diagnosis survival. Mixture Cure Modeling (MCM) has been proposed for projecting survival impact with MCED tests because it includes a proportion of cured patients which is less sensitive to lead time bias. This study explores the impact of using MCM vs a simple extrapolation of survival on the cost-effectiveness of MCED testing.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
